According to Prophecy Market Insights “Non-Alcoholic Steatohepatitis Biomarkers Market accounted for US$ 556.6 billion in 2019 and is estimated to be US$ 8177.9 billion by 2029 and is anticipated to register a CAGR of 31.3%” COVINA, Calif., May 18, 2023 /PRNewswire/ — What is the Overview of Non-Alcoholic Steatohepatitis Biomarkers Market? Non-alcoholic steatohepatitis (NASH) is the … Read more
HSINCHU, May 18, 2023 /PRNewswire/ — Smart manufacturing & stringent process control enhance TPU quality. ICP DAS – BMP (Biomedical Polymers), a Taiwan-based supplier of medical-grade TPU (thermoplastic polyurethane), acts as a front-runner who deploys IIoT systems in a smart factory to maintain lot-to-lot consistency in TPU production. The company will showcase its prime quality … Read more
SHANGHAI, May 18, 2023 /PRNewswire/ — Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced a strategic collaboration with UroViu Corporation (“UroViu”). Asieris Pharmaceuticals will obtain exclusive global rights to UroViu’s patented technology of portable single-use cystoscope in … Read more
IAB56 RPT agent is designed to target integrin αvβ6, a receptor over-expressed in a broad range of solid cancers underserved by current cancer therapies. IAB57 RPT agent is designed to target DLL3, a target over-expressed in cancer tissues and relevant in several cancers, most notably Small-Cell Lung Cancer (SCLC) LOS ANGELES, May 18, 2023 /PRNewswire/ … Read more
IAB56 RPT agent is designed to target integrin αvβ6, a receptor over-expressed in a broad range of solid cancers underserved by current cancer therapies. IAB57 RPT agent is designed to target DLL3, a target over-expressed in cancer tissues and relevant in several cancers, most notably Small-Cell Lung Cancer (SCLC) LOS ANGELES, May 18, 2023 /PRNewswire/ … Read more
Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in adult patients on haemodialysis ST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 /PRNewswire/ — Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that … Read more
Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in adult patients on haemodialysis ST. GALLEN, Switzerland and STAMFORD, Conn., May 18, 2023 /PRNewswire/ — Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that … Read more
Company sets refreshed global strategy and new US initiatives for Oxiplex® portfolio of adhesion barrier products in women’s health, spine, orthopedics and general surgery. SAN LUIS OBISPO, Calif., May 17, 2023 /PRNewswire/ — FzioMed, Inc. (“FzioMed” or the “Company”), a global leading surgical biomaterials company focused on spine, orthopedic, peritoneal and gynecological surgery, today announced … Read more
WATERTOWN, Mass., May 17, 2023 /PRNewswire/ — Fluent BioSciences, a top life sciences company focusing on bringing the benefits of high-quality single-cell biology to all laboratories by offering scalable, cost-effective, and easy-to-implement scRNA-seq solutions, in collaboration with GenomeWeb and the Liddelow Lab, will host a webinar to explore the use of PIPseq, an innovative single-cell … Read more
– ATG-031, discovered and developed in-house by Antengene, is the world’s first anti-CD24 antibody to advance to the clinic in oncology and Antengene’s third drug candidate to enter clinical studies in the U.S. – The Phase I “PERFORM” study will evaluate the safety and tolerability, pharmacology, immunogenicity, and preliminary efficacy of ATG-031 in patients with … Read more